- Poster presentation
- Open Access
Prevalence of drug resistance mutations in HIV-1 protease gene from North India
© Azam et al; licensee BioMed Central Ltd. 2012
- Published: 4 May 2012
- Protease Gene
- Drug Resistance Mutation
- Line Drug
- Mutation M46I
- Good Therapeutic Outcome
Success of combination ART therapy in treating HIV infection is hampered due to emergence of drug resistant mutations in polymerase gene. The present study was conducted to find out the prevalence of drug resistance-conferring mutations in protease gene in HIV-1 infected patients.
CD4 cells estimation was done in all patients. The protease gene was amplified from pro-viral DNA by nested PCR and then sequenced. Mutational analysis and subtyping were done by using Stanford database and REGA HIV-1 subtyping tool, respectively.
Among 35 patients, there were 17 drug naïve and 18 first line drugs experienced HIV-1 infected patients (22 males & 13 females; mean age: 35.95 years; mean CD4 cells: 216.4cells/mm3). Majority of our patients showed mutations at T12S/T (82.85%), K14R (40%), I15V (71.42%), L19I/T/V/M (97.14%), M36I (71.42%), R41K (88.57%), L63P (65.71%), H63K (100%) and L89M (74.28%) positions in both group of patients while other mutations were at positions 35, 37, 45, 60, 62, 77, and 82 in few cases. Interestingly, one first line drug experienced patient showed major DR mutations at D30N and M46I positions. Majority (94.28%) was belonging to subtype C and 2 patients were belonging to subtypes A (A1).
HIV-1 subtype C predominates in northern India followed by subtype A. Major DR mutation M46I are suggested to confer low levels of resistance to ATV, FPV, IDV, LPV, NFV and TPV.D30N confers resistance only to NFV. Resistance testing in HIV-1 infected patients should be performed before the initiation of therapy for better therapeutic outcome.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.